Omnicell, Inc. (NASDAQ:OMCL) Receives $52.33 Consensus Price Target from Analysts

Omnicell, Inc. (NASDAQ:OMCL) has been assigned an average recommendation of “Hold” from the six ratings firms that are currently covering the company, MarketBeat.com reports. Four research analysts have rated the stock with a hold recommendation and two have assigned a buy recommendation to the company. The average twelve-month price objective among brokerages that have issued ratings on the stock in the last year is $52.33.

A number of analysts have issued reports on the company. Benchmark reaffirmed a “buy” rating and issued a $62.00 target price on shares of Omnicell in a research note on Tuesday, February 4th. StockNews.com raised Omnicell from a “hold” rating to a “buy” rating in a research note on Thursday, March 6th. JPMorgan Chase & Co. increased their price target on Omnicell from $37.00 to $44.00 and gave the stock a “neutral” rating in a report on Thursday, November 21st. Bank of America lowered their price target on Omnicell from $54.00 to $46.00 and set a “neutral” rating for the company in a report on Monday, January 6th. Finally, Wells Fargo & Company lowered their price target on Omnicell from $49.00 to $40.00 and set an “equal weight” rating for the company in a report on Monday, January 13th.

Omnicell Stock Down 0.9 %

NASDAQ OMCL opened at $32.93 on Friday. Omnicell has a one year low of $25.12 and a one year high of $55.75. The company has a market cap of $1.54 billion, a P/E ratio of 121.97, a P/E/G ratio of 7.53 and a beta of 0.85. The business has a fifty day moving average price of $40.27 and a 200 day moving average price of $43.10. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.22 and a current ratio of 1.37.

Omnicell (NASDAQ:OMCL) last issued its earnings results on Thursday, February 6th. The company reported $0.45 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.57 by ($0.12). Omnicell had a return on equity of 3.82% and a net margin of 1.13%. Research analysts anticipate that Omnicell will post 1.09 EPS for the current fiscal year.

Hedge Funds Weigh In On Omnicell

Hedge funds and other institutional investors have recently bought and sold shares of the company. Pier Capital LLC purchased a new position in Omnicell during the 3rd quarter valued at about $5,859,000. Royce & Associates LP purchased a new position in Omnicell during the 3rd quarter valued at about $811,000. Geode Capital Management LLC boosted its holdings in Omnicell by 0.3% during the 3rd quarter. Geode Capital Management LLC now owns 1,104,745 shares of the company’s stock valued at $48,176,000 after acquiring an additional 2,877 shares during the period. Connor Clark & Lunn Investment Management Ltd. boosted its holdings in Omnicell by 750.5% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 294,037 shares of the company’s stock valued at $12,820,000 after acquiring an additional 259,463 shares during the period. Finally, Intech Investment Management LLC acquired a new stake in Omnicell in the 3rd quarter valued at about $753,000. 97.70% of the stock is currently owned by hedge funds and other institutional investors.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.